Clinical Trials Logo

Clinical Trial Summary

The aim of the current study is to investigate the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) defined as patients who present with features of diffuse fibrosing lung disease of >10% extent on high-resolution computed tomography (HRCT) and whose lung function and respiratory symptoms or chest imaging have worsened despite treatment with unapproved medications used in clinical practice to treat ILD. There is currently no efficacious treatment available for PF-ILD. Based on its efficacy and safety in Idiopathic Pulmonary Fibrosis (IPF), it is anticipated that Nintedanib will be a new treatment option for patients with PF-ILD.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT02999178
Study type Interventional
Source Boehringer Ingelheim
Status Completed
Phase Phase 3
Start date January 17, 2017
Completion date August 12, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04559581 - Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
Recruiting NCT02543073 - MSC for Treatment of Interstitial Lung Disease After Allo-HSCT Phase 1/Phase 2
Completed NCT02251964 - Rituximab in Interstitial Pneumonitis Phase 2/Phase 3
Terminated NCT01432080 - Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant Phase 2
Completed NCT01442779 - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04016168 - Idiopathic Pulmonary Fibrosis and Serum Bank
Recruiting NCT00258583 - Dorothy P. and Richard P. Simmons Center for ILD Research Registry
Recruiting NCT04159129 - Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients
Active, not recruiting NCT03313180 - A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis. Phase 3
Completed NCT03136120 - Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease
Recruiting NCT04702893 - INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
Completed NCT03099187 - A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease Phase 2
Not yet recruiting NCT04707781 - Database for Interstitial Lung Disease
Recruiting NCT03596528 - Interstitial Lung Disease (ILD). Diagnostic Yield of Surgical Lung Biopsy Versus Cryobiopsy in the Same Surgical Stage. N/A
Not yet recruiting NCT03858842 - Non-interventional Study Describing Epidemiology, Prognosis and Patient Healthcare Costs in France, 2010-2017
Not yet recruiting NCT02705144 - Definition of the Status of the Human Lung Stem Cell Niches ex Vivo in Tissue Biopsies Performed in Patients With Emphysema and Interstitial Fibrosis N/A
Completed NCT01553981 - A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Phase 3
Active, not recruiting NCT04100226 - Vitamin D Deficiency and Effect of Its Supplementation on Interstitial Lung Diseases(ILD). N/A
Recruiting NCT04354220 - Capnography Monitoring in Ventilated Children
Recruiting NCT01374542 - Respiratory Endoscopy: Diagnostic Yield, Technical Factors and Complications